BridgeBio's Attruby Gains Analyst Confidence with Promising Launch Outlook
核心洞察
BridgeBio's Attruby receives positive analyst ratings due to its early FDA approval for ATTR-CM (搜索) and potential for widespread adoption.
Attruby's competitive pricing, 10% lower than tafamidis, and favorable insurance coverage are expected to drive market penetration.
Analyst surveys indicate strong interest in Attruby, with over 30% of first-line patients likely to be treated with the drug.
BridgeBio Pharma's Attruby (acoramidis) has garnered increased confidence from analysts following its recent FDA approval for the treatment of transthyretin (搜索) amyloid cardiomyopathy (ATTR-CM (搜索)). The positive sentiment is driven by the drug's early approval, favorable pricing strategy, and promising adoption rates among physicians.
Analyst Reaffirmations and Price Target Adjustments
TD Cowen reaffirmed a Buy rating on BridgeBio shares, citing Attruby's effectiveness in reducing cardiovascular hospitalizations and deaths, achieving near-complete stabilization for patients, a benefit not observed with tafamidis. H.C. Wainwright also raised its price target on BridgeBio to $49.00, maintaining a Buy rating, following the FDA approval. Piper Sandler confirmed its Overweight rating with a price target of $46.00.
Competitive Pricing and Market Adoption
Attruby's pricing is set at $18,759.12 for a 28-day supply, approximately $244,500 annually, which is 10% lower than tafamidis ($268,000 annually) and significantly less than Amvuttra. This competitive pricing, coupled with minimal co-pay expenses for most patients, is projected to encourage widespread adoption. A Key Opinion Leader (KOL) survey conducted by TD Cowen indicates that over 30% of first-line patients are likely to be treated with Attruby.
Clinical Data and Mechanism of Action
The FDA approval of Attruby was based on the ATTRibute-CM Phase 3 study, which demonstrated a significant reduction in death and cardiovascular-related hospitalizations. Attruby is an orally-administered drug designed to emulate a "rescue mutation" of the TTR gene, stabilizing the native TTR tetramer and addressing the root cause of ATTR-CM (搜索).
Medicare Coverage Considerations
Piper Sandler highlighted the implications of potential approval for ALNY's Amvuttra in ATTR-CM (搜索), noting the differences in Medicare drug coverage under Part B and Part D. Amvuttra would fall under Part B coverage, while Attruby is covered under Part D. This distinction is significant as Medicare covers an estimated 80% of ATTR-CM patients. Payer consultants suggest a potentially higher liability for insurers with a Part B drug compared to a Part D medication, which may influence market adoption.
Pipeline Developments Beyond Attruby
BridgeBio is also advancing its pipeline with gene therapy programs. Encouraging results were reported from the Phase 1/2 CANaspire trial for BBP-812, a gene therapy for Canavan disease (搜索), suggesting potential improvements in motor function. Enrollment has been completed for the Phase 3 FORTIFY study of BBP-418, a potential treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (搜索). The company discontinued its BBP-631 gene therapy program, expected to save over $50 million in research and development, and formed a joint venture named GondolaBio, backed by a $300 million investment.